The study linked below documents a case of “44-year-old female with a recurrent, multicentric, malignant glioma-“anaplastic astrocy-toma (WHO Grade III).”” This women underwent both conventional chemotherapy and radiation. Her brain cancer continued to grow and spread. She then underwent “sodium phenylbutyrate” and then acheived a 4-year remission as of the writing of this article.
After several years of conventional therapies for my blood cancer, multiple myeloma, I reached “end-stage” by 9/97. I underwent antineoplaston therapy (ANP) from 11/3/97-4/3/99. ANP therapy offers a viable therapy option for those who’s cancer diagnoses are problematic.
Burzynski and ANP therapy is controversial to say the least. I can say without a doubt that ANP put me into complete remission where I remain today.
Glioblastoma Multiforme (GBM) is an aggressive form of brain cancer that conventional oncology has difficulty treating. There are a number of non-conventional therapies written about on PeopleBeatingCancer that offer real hope for the GBM patient.
I a both a cancer survivor and cancer coach. For more information about conventional, integrative and non-conventional GBM therapies scroll down the page, post a question or comment and I will reply ASAP.
“Sodium phenylbutyrate is a biological-response modifier that acts as a dose-dependent inhibitor of glioma cell proliferation, migration, and invasiveness in vitro, possibly by inhibition of urokinase and c-myc pathways. Despite its biological activity in vitro, there have not been any prior reports of efficacy in the treatment of human malignant gliomas. We report a 44-year-old female with a recurrent, multicentric, malignant glioma who experienced a durable remission lasting more than four years…
The patient was started on sodium phenylbutyrate, 18 g daily in three divided oral doses, and reduced to 9 g/day and eventually to 4.5 g/day to eliminate mild, reversible side effects.
Four years later, the patient has a KPS functional score of 100%. Phenylbutyrate is a well-tolerated, oral agent that shows potential for the treatment of malignant gliomas…”